{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477235775
| IUPAC_name = (2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone
| image = AM-1241-2D-skeletal.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 3316
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 444912-48-5
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 10141893
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8317404
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 408430

<!--Chemical data-->
| C=22 | H=22 | I=1 | N=3 | O=3 
| molecular_weight = 503.333 g/mol
| smiles = Ic2ccc(N(=O)=O)cc2C(=O)c(c4ccccc14)cn1CC3CCCCN3C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZUHIXXCLLBMBDW-UHFFFAOYSA-N
}}

'''AM-1241''' (1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole) is a chemical from the [[aminoalkylindole]] family that acts as a potent and selective [[agonist]] for the [[cannabinoid receptor]] [[Cannabinoid receptor 2|CB<sub>2</sub>]],<ref name="pmid16894349">{{cite journal |author =Yao BB |title=In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? |journal=[[British Journal of Pharmacology]] |volume=149 |issue=2 |pages=145–54 |date=September 2006 |pmid=16894349 |pmc=2013801 |doi=10.1038/sj.bjp.0706838 |display-authors=etal}}</ref><ref name="pmid17549048">{{cite journal |author =Bingham B |title=Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers |journal=British Journal of Pharmacology |volume=151 |issue=7 |pages=1061–70 |date=August 2007 |pmid=17549048 |pmc=2042933 |doi=10.1038/sj.bjp.0707303 |display-authors=etal}}</ref> with a [[Dissociation constant|K<sub>i</sub>]] of 3.4nM at CB<sub>2</sub> and 80x selectivity over the related [[Cannabinoid receptor 1|CB<sub>1</sub>]] receptor.<ref name="pmid12917492">{{cite journal |author =Ibrahim MM |title=Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS |journal=Proceedings of the National Academy of Sciences of the United States of America |volume=100 |issue=18 |pages=10529–33 |date=September 2003 |pmid=12917492 |pmc=193595 |doi=10.1073/pnas.1834309100 |display-authors=etal}}</ref><ref name="pmid18289088">{{cite journal |vauthors =Marriott KS, Huffman JW |title=Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor |journal=Current Topics in Medicinal Chemistry |volume=8 |issue=3 |pages=187–204 |year=2008 |pmid=18289088 |doi= 10.2174/156802608783498014 }}</ref> It has [[analgesic]] effects in animal studies, particularly against "atypical" pain such as [[hyperalgesia]] and [[allodynia]].<ref name="pmid16553616">{{cite journal |author =Beltramo M |title=CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms |journal=The European Journal of Neuroscience |volume=23 |issue=6 |pages=1530–8 |date=March 2006 |pmid=16553616 |doi=10.1111/j.1460-9568.2006.04684.x |display-authors=etal}}</ref> This is thought to be mediated through CB<sub>2</sub>-mediated peripheral release of endogeous [[opioid peptide]]s,<ref name="pmid15705714">{{cite journal |author =Ibrahim MM |title=CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids |journal=Proceedings of the National Academy of Sciences of the United States of America |volume=102 |issue=8 |pages=3093–8 |date=February 2005 |pmid=15705714 |pmc=549497 |doi=10.1073/pnas.0409888102 |display-authors=etal}}</ref> as well as direct activation of the [[Transient receptor potential cation channel, member A1|TRPA1 channel]].<ref name="pmid18234885">{{cite journal |vauthors =Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM |title=Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation |journal=Journal of Neuroscience |volume=28 |issue=5 |pages=1064–75 |date=January 2008 |pmid=18234885 |doi=10.1523/JNEUROSCI.1565-06.2008 }}</ref> It has also shown efficacy in the treatment of [[amyotrophic lateral sclerosis]] in animal models.<ref name="pmid16781706">{{cite journal |vauthors =Kim K, Moore DH, Makriyannis A, Abood ME |title=AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis |journal=European Journal of Pharmacology |volume=542 |issue=1-3 |pages=100–5 |date=August 2006 |pmid=16781706 |doi=10.1016/j.ejphar.2006.05.025 }}</ref><ref name="pmid17241118">{{cite journal |author =Shoemaker JL |title=The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset |journal=Journal of Neurochemistry |volume=101 |issue=1 |pages=87–98 |date=April 2007 |pmid=17241118 |doi=10.1111/j.1471-4159.2006.04346.x |pmc=2819701|display-authors=etal}}</ref>

==Effects in bone cancer model==
The antihyperalgesic effects of AM-1241 were investigated in a [[murine]] bone cancer model. [[Sarcoma]] cells were injected into the femur of a mouse, and then mice were injected twice daily with AM-1241. Treatment with AM-1241 reduced both spontaneous and evoked pain, as well as reducing the bone loss and subsequent fractures due to the tumor. Pretreatment with the CB<sub>2</sub> antagonist [[SR-144,528]] reversed the acute effects of AM-1241 on both spontaneous and evoked pain, while having no effect on its own.<ref name=Lozano>{{cite journal|last=Lozano|first=Alysia|title=A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss|journal=Life Sciences|date=April 2010|pages=646–53|pmid=20176037|doi=10.1016/j.lfs.2010.02.014|volume=86|issue=17-18|pmc=2871326}}<!--|accessdate=18 December 2011--></ref>

==See also==
* [[AM-1220]]
* [[AM-1248]]
* [[AM-2233]]

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Aminoalkylindoles]]
[[Category:Benzoylindoles]]
[[Category:Piperidines]]
[[Category:Nitrobenzenes]]
[[Category:Iodoarenes]]
[[Category:AM cannabinoids]]
[[Category:Designer drugs]]


{{cannabinoid-stub}}